Finance

Lists
Why is PRME up 9.03%?
Dive Deeper
PRME:NASDAQ
Prime Medicine, Inc
$3.50
+9.03%
(+0.29) 1D
$3.45
-1.43% (-0.050)
After hours
Closed: Oct 6, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRME...
Open
$3.56
High
$3.72
Low
$3.26
Mkt. cap
589.33M
Avg. vol.
3.08M
Volume
12.02M
52-wk high
$6.85
52-wk low
$2.67
EPS
-$1.09
Beta
2.37
Shares outstanding
181.38M
No. of employees
146
Open
$3.56
High
$3.72
Low
$3.26
Mkt. cap
589.33M
Avg. vol.
3.08M
Volume
12.02M
52-wk high
$6.85
52-wk low
$2.67
EPS
-$1.09
Beta
2.37
Shares outstanding
181.38M
No. of employees
146
News stories
From web sources and news partners
Profile
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts. Wikipedia
About Prime Medicine, Inc
CEO-
Employees146
Founded2019
Headquarters-
SectorBiotechnology
Websiteprimemedicine.com
Analyst ratings
Based on 8 analysts giving stock ratings to PRME in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for PRME in the last 3 months.
Highest
Current $3.50
$11.00 (+214.29%)
Average
$7.67 (+119.14%)
Lowest
$5.00 (+42.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Cory Jubinville, PhD
LifeSci Capital
Buy
Maintained
$6.00
+71.4%
10/05/2026
Arthur He CFA
H.C. Wainwright
Buy
Reiterated
$8.00
+128.6%
10/01/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$11.00
+214.3%
09/25/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$11.00
+214.3%
09/25/2026
David Lebowitz
BMO Capital
Buy
Maintained
$9.00
+157.1%
09/24/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/24/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$7.00
+100%
09/24/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$9.00
+157.1%
08/19/2026
Terence Flynn
Morgan Stanley
Hold
Reiterated
-
-
08/10/2026
Boris Peaker
JonesTrading
Buy
Maintained
$5.00
+42.9%
08/06/2026
Unknown Analyst
Wedbush
Buy
Maintained
$8.00
+128.6%
06/22/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$9.00
+157.1%
05/08/2026
Soumit Roy
JonesTrading
Buy
Maintained
$5.00
+42.9%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.22M
838.00K
856.00K
1.15M
Cost of goods sold
43.99M
34.71M
34.10M
33.40M
Cost of revenue
43.99M
34.71M
34.10M
33.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.21M
14.74M
17.40M
11.04M
Operating expense
11.21M
14.74M
17.40M
11.04M
Total operating expenses
55.20M
49.45M
51.51M
44.44M
Operating income
-53.97M
-48.61M
-50.65M
-43.28M
Other non operating income
44.00K
49.00K
51.00K
55.00K
EBT including unusual items
-50.58M
-46.08M
-49.12M
-42.11M
EBT excluding unusual items
-52.79M
-47.48M
-49.58M
-42.44M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-50.58M
-46.08M
-49.12M
-42.11M
Net profit margin
-4,129.14%
-5,498.69%
-5,738.55%
-3,648.96%
Earnings per share
-0.32
-0.24
-0.28
-0.24
Interest and investment income
1.14M
1.08M
1.02M
788.00K
Interest expense
-
-
-
-
Net interest expenses
1.14M
1.08M
1.02M
788.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-52.09M
-46.73M
-48.80M
-41.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps